Publications en collaboration avec des chercheurs de Hospital Universitario 12 de Octubre (135)

2025

  1. Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma

    Blood Advances, Vol. 9, Núm. 3, pp. 571-582

  2. Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy

    American Journal of Hematology, Vol. 100, Núm. 1, pp. 93-102

  3. Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

    Journal of Clinical Oncology, Vol. 43, Núm. 24, pp. 2679-2691

  4. Factors Increasing the Risk of Infection in Patients With Multiple Myeloma: From Biology to Prevention

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 25, Núm. 10, pp. e844-e856.e1

  5. High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

    Blood, Vol. 146, Núm. 15, pp. 1747-1758

  6. High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy

    HemaSphere, Vol. 9, Núm. 4

  7. Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial

    The Lancet Haematology, Vol. 12, Núm. 8, pp. e588-e598

  8. Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 25, Núm. 7, pp. 494-504

  9. Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN–HARMONY Alliance platform

    HemaSphere, Vol. 9, Núm. 10

  10. Macrophage activation syndrome-like in multiple myeloma patients treated with the academic CAR-T against BCMA ARI0002h

    Frontiers in Immunology, Vol. 16

  11. Minimally Invasive Assessment of Peripheral Residual Disease during Maintenance or Observation in Transplant-Eligible Patients with Multiple Myeloma

    Journal of Clinical Oncology, Vol. 43, Núm. 2, pp. 125-132

  12. Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment

    Blood, Vol. 146, Núm. 8, pp. 964-970

2024

  1. 30-Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis

    HemaSphere

  2. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

    Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096

  3. Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

    Advances in Therapy, Vol. 41, Núm. 2, pp. 696-715

  4. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

    The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

  5. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

    Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

  6. Expression profile of Bcl-2 family proteins in newly diagnosed multiple myeloma patients

    HemaSphere, Vol. 8, Núm. 12

  7. High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience

    HemaSphere, Vol. 8, Núm. 12

  8. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

    Annals of Hematology, Vol. 103, Núm. 12, pp. 5651-5661